25B-NBOMe

25B-NBOMe
Clinical data
Other names	NBOMe-2C-B; Cimbi-36; Nova; BOM 2-CB; N-(2-Methoxybenzyl)-4-bromo-2,5-dimethoxyphenethylamine
Routes of; administration	Sublingual, buccal, intranasal
Drug class	Serotonin 5-HT2 receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code	None;
Legal status
Legal status	BR: Class F2 (Prohibited psychotropics); DE: Anlage I (Authorized scientific use only); UK: Class A; US: Schedule I; UN: Psychotropic Schedule I;
Pharmacokinetic data
Metabolites	5-DM-25B-NBOMe
Onset of action	45–75 minutes or 15–120 minutes
Duration of action	8–12 hours
Identifiers
	IUPAC name 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine;
CAS Number	1026511-90-9 ;
PubChem CID	9977044;
ChemSpider	8152636 ;
UNII	S6NAA81PHK;
KEGG	C22773;
CompTox Dashboard (EPA)	DTXSID50907974 ;
Chemical and physical data
Formula	C18H22BrNO3
Molar mass	380.282 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=CC=CC=C1CNCCC2=CC(=C(C=C2OC)Br)OC;
	InChI InChI=1S/C18H22BrNO3/c1-21-16-7-5-4-6-14(16)12-20-9-8-13-10-18(23-3)15(19)11-17(13)22-2/h4-7,10-11,20H,8-9,12H2,1-3H3 ; Key:SUXGNJVVBGJEFB-UHFFFAOYSA-N ;
	(verify)

25B-NBOMe, also known as NBOMe-2C-B, Cimbi-36, or as N-(2-methoxybenzyl)-4-bromo-2,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine, 2C, and 25-NB (NBOMe) families. It is the N-(2-methoxybenzyl) derivative of 2C-B. The drug is taken sublingually, bucally, or intranasally.

25B-NBOMe was first described in the scientific literature by Ralf Heim and colleagues at the Free University of Berlin by 1999. After 25I-NBOMe and along with 25C-NBOMe, 25B-NBOMe is one of the most widely used 25-NB psychedelics.